找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Messenger RNA Therapeutics; Stefan Jurga,Jan Barciszewski Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive licen

[复制链接]
查看: 47133|回复: 63
发表于 2025-3-21 17:00:26 | 显示全部楼层 |阅读模式
书目名称Messenger RNA Therapeutics
编辑Stefan Jurga,Jan Barciszewski
视频video
概述Focuses on the fundamentals and applications of messenger RNA (mRNA)-based therapeutics.Discusses the strengths and key challenges of this emerging class of drugs.Provides a state-of-the-art overview
丛书名称RNA Technologies
图书封面Titlebook: Messenger RNA Therapeutics;  Stefan Jurga,Jan Barciszewski Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive licen
描述This book focuses on the fundamentals and applications of messenger RNA (mRNA)-based therapeutics and discusses the strengths and key challenges of this emerging class of drugs. In the past 30 years, extensive research and technological development in many areas have contributed to the emergence of in vitro transcribed mRNA as a therapeutic that has now reached clinical testing. Formulations that protect the mRNA from nucleases and accelerate its cellular uptake, combined with improvements to the mRNA molecules themselves, have been critical advancements for mRNAs to become viable therapeutics. Though once regarded as a serious impediment, the transient nature of mRNA technology is now considered a major advantage in making mRNA therapies safe and, ultimately, a potential game changer in the field of medicine. .This new book in the .RNA Technologies. series provides a state-of-the-art overview on the emerging field of mRNA therapeutics covering essential strategies for formulation, delivery, and application. It also reviews the promising role in cancer immunotherapy, respiratory diseases, and chronic HBV infection and discusses RNA vaccines in light of the current COVID-19 pandemic
出版日期Book 2022
关键词mRNA therapeutics; RNA vaccines; SARS-CoV-2; Lipid nanoparticles; Adjuvants; Cancer Immunotherapy; Self-am
版次1
doihttps://doi.org/10.1007/978-3-031-08415-7
isbn_softcover978-3-031-08417-1
isbn_ebook978-3-031-08415-7Series ISSN 2197-9731 Series E-ISSN 2197-9758
issn_series 2197-9731
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

书目名称Messenger RNA Therapeutics影响因子(影响力)




书目名称Messenger RNA Therapeutics影响因子(影响力)学科排名




书目名称Messenger RNA Therapeutics网络公开度




书目名称Messenger RNA Therapeutics网络公开度学科排名




书目名称Messenger RNA Therapeutics被引频次




书目名称Messenger RNA Therapeutics被引频次学科排名




书目名称Messenger RNA Therapeutics年度引用




书目名称Messenger RNA Therapeutics年度引用学科排名




书目名称Messenger RNA Therapeutics读者反馈




书目名称Messenger RNA Therapeutics读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

1票 100.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 20:29:37 | 显示全部楼层
发表于 2025-3-22 02:16:56 | 显示全部楼层
Messenger RNA Therapeutics: Start of a New Era in Medicine,ses of RNA-based therapeutics. Among these, mRNA-based therapy is centered on producing proteins within the cells to supplant deficient or abnormal proteins and in vaccination to a target pathogen. The potential of mRNA therapeutics is evident from the two major mRNA vaccines approved for COVID-19:
发表于 2025-3-22 08:11:30 | 显示全部楼层
Hospital-Based RNA Therapeutics,e mRNA is essentially biological software, therapeutic RNA constructs can be rapidly developed. The generation of small batches of clinical-grade mRNA to support IND applications and first-in-man clinical trials, as well as personalized mRNA therapeutics delivered at the point-of-care, is feasible a
发表于 2025-3-22 08:55:02 | 显示全部楼层
发表于 2025-3-22 14:11:04 | 显示全部楼层
SARS-COV-2 and Other mRNA Vaccines, for the prevention of SARS-COV-2 disease following unprecedented speed of development through to emergency use licensure in around three hundred days from virus sequence availability. Case studies of three SARS-COV-2 mRNA vaccines for which field clinical efficacy data are available are examined an
发表于 2025-3-22 17:09:04 | 显示全部楼层
发表于 2025-3-23 00:37:51 | 显示全部楼层
Synthetic mRNA Gene Therapies and Hepatotropic Non-viral Vectors for the Treatment of Chronic HBV Ience of HBV-associated liver cancer and cirrhosis. Currently, there is no cure for chronic HBV infection, and novel therapeutic approaches, including gene editing and epigenome engineering, are being investigated. Although promising, the liver-specific delivery, expression and safety profile of thes
发表于 2025-3-23 04:44:45 | 显示全部楼层
,Preparation of Synthetic mRNAs—Overview and Considerations,afe. The central advantage of the successful use of synthetic mRNA as a vaccine hinge on being able to rapidly manufacture the mRNA molecules. The synthetic mRNA is prepared in vitro via a cell-free enzymatic process. The aim of this chapter is to provide an overview of the enzymatic mRNA synthesis
发表于 2025-3-23 06:45:38 | 显示全部楼层
In Vitro-Transcribed mRNAs as a New Generation of Therapeutics in the Dawn of Twenty-First Century:an efficient delivery system, the host cell ribosomes will be recruited to translate and produce the corresponding desired proteins. Nowadays, about 20 years after the first report as for the use of IVT-mRNA, this technology has all the spotlight on it, due to the recently produced vaccines against
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-25 12:32
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表